Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: a case report

Abstract Background Recent advances in cancer immunotherapy have been remarkable, with many reports on the clinical effects of immune checkpoint inhibitors. Nivolumab has been covered by the national health insurance in Japan as a third-line agent for advanced and recurrent gastric cancer since Sept...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Tomoya Takami, Koji Yasuda, Nozomi Uozumi, Yutaka Musiake, Hiroshi Shintani, Naoki Kataoka, Tomoyuki Yamaguchi, Shinichiro Makimoto
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2021-12-01
Edice:	Journal of Medical Case Reports
Témata:	Nivolumab Advanced gastric cancer Complete response Prognosis
On-line přístup:	https://doi.org/10.1186/s13256-021-03200-x
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!